drugset
drugset / Trial / NCT03697629

A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

NCT03697629 ↗

Phase 2 Completed 40 enrolled Canadian Myeloma Research Group
NaSingle-groupOpen-labelTreatment

Summary

Primary objective: To determine the incidence of infusion related reactions (IRR's) in the first 6 months of daratumumab administration.

Timeline

Start
2018-12-03
Primary completion
2020-07-21
Completion
2021-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Daratumumab Monoclonal antibody 16 mg/kg —

Indications

plasma cell myeloma